6CM
LXEO icon

683 Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

683 Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.73M Buy
1,875,000
+675,000
+56% +$3.65M 0.43% 55
2026
Q1 		$6.89M Buy
1,200,000
+80,000
+7% +$567K 0.36% 58
2025
Q4 		$11.1M Buy
1,120,000
+197,338
+21% +$1.8M 0.48% 46
2025
Q3 		$6.13M Buy
+922,662
New +$4.46M 0.32% 65

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

683 Capital Management's LXEO Position: Q2 2026 in Review

683 Capital Management increased its Lexeo Therapeutics (LXEO) stake by 56% in Q2 2026, buying an estimated $3.65M and bringing the position to 1,875,000 shares worth $8.73M. The position accounts for 0.43% of the portfolio, ranked #55.

683 Capital Management first reported a position in LXEO in Q3 2025 and has held it in 4 quarters since. The position peaked at $11.1M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • 683 Capital Management held 1,875,000 shares of Lexeo Therapeutics worth $8.73M as of Q2 2026.
  • 683 Capital Management bought 675,000 Lexeo Therapeutics shares in Q2 2026, an estimated $3.65M.
  • Lexeo Therapeutics made up 0.43% of 683 Capital Management's portfolio in Q2 2026, its #55 holding.
  • 683 Capital Management first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 683 Capital Management's Lexeo Therapeutics position peaked at $11.1M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.